Full Text View
Tabular View
No Study Results Posted
Related Studies
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
This study is currently recruiting participants.
Study NCT00072358   Information provided by National Cancer Institute (NCI)
First Received: November 4, 2003   Last Updated: September 18, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neuroblastoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Interventions listed in this trial
monoclonal antibody 3F8
sargramostim
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Immunoglobulins
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services